Dexcel patents expiration
1. Esomeprazole Magnesium patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10076494 | DEXCEL | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(12 years from now) | |
| US10835488 | DEXCEL | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(12 years from now) | |
Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient
Market Authorisation Date: 20 October, 2020
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM family patents
2. Hemady patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11304961 | DEXCEL | Compositions comprising dexamethasone |
Dec, 2037
(13 years from now) | |
| US10537585 | DEXCEL | Compositions comprising dexamethasone |
Dec, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-271) | Oct 03, 2026 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 03 October, 2019
Treatment: A method of treating adults with multiple myeloma using dexamethasone in combination with an anti-myeloma product
Dosage: TABLET;ORAL
HEMADY family patents
3. Lansoprazole patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11077055 | DEXCEL | Orally disintegrating compositions |
Apr, 2036
(11 years from now) | |
Drugs and Companies using LANSOPRAZOLE ingredient
Market Authorisation Date: 07 June, 2016
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
LANSOPRAZOLE family patents
4. Omeprazole patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10835488 | DEXCEL | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(12 years from now) | |
| US10076494 | DEXCEL | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(12 years from now) | |
Drugs and Companies using OMEPRAZOLE ingredient
Market Authorisation Date: 05 July, 2017
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
OMEPRAZOLE family patents